FoxFeed Blog
Today there are more therapies to slow or stop Parkinson's in human trials than ever before. But those treatments face challenges in proving their effectiveness, and we want to ensure that even more potential therapies enter clinical testing.
Objective, biological markers of Parkinson's disease -- called biomarkers -- would be a game-changer. A perspective published today in the journal Science Translational Medicine lays out the needs and opportunities in Parkinson's biomarker research.
No hay comentarios:
Publicar un comentario